MedTrace Logo

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

NCT01740362 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-01-07

Study results available
· View outcomes & findings →

Summary

A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.

Conditions

  • Renal Impairment

Interventions

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2004-03-31
Completion
2004-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01740362 on ClinicalTrials.gov